drugset / Trial / NCT00226954
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary: To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently. Secondary Objectives: To describe the safety and tolerability at this dose and schedule
Timeline
- Start
- 2003-03
- Primary completion
- 2007-11
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zoledronic acid | Other / unclassified | — | — |